<SEC-DOCUMENT>0001437749-20-012220.txt : 20200601
<SEC-HEADER>0001437749-20-012220.hdr.sgml : 20200601
<ACCEPTANCE-DATETIME>20200601164038
ACCESSION NUMBER:		0001437749-20-012220
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200601
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200601
DATE AS OF CHANGE:		20200601

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		20933888

	BUSINESS ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		(434) 220-0718

	MAIL ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dffn20200601_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html><head>
	<title>dffn20200601_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 6/1/2020 4:32:24 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&nbsp;</p>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt; margin: 0pt; text-transform: uppercase; text-align: center;"><b>UNITED STATES</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Washington, D.C. 20549</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;">________________</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 18pt; margin: 0pt; text-transform: uppercase; text-align: center;"><b>FORM 8-K</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-transform: uppercase; text-align: center;"><b>CURRENT REPORT</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Pursuant to Section 13 or 15(d) of</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>the Securities Exchange Act of 1934</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;">__________________</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Date of Report (Date of earliest event reported): </b><b>June 1</b><b>, 2020</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;">___________________</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:18pt;margin:0pt;text-align:center;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Exact name of registrant as specified in its charter)</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:33.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Delaware</b></p>
			</td>
			<td style="vertical-align:top;width:33.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>000-24477</b></p>
			</td>
			<td style="vertical-align:top;width:33.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>30-0645032</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:33.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(State or other jurisdiction of</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">incorporation)</p>
			</td>
			<td style="vertical-align:top;width:33.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Commission File</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Number)</p>
			</td>
			<td style="vertical-align:top;width:33.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(I.R.S. Employer</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Identification No.)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:42.5pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>1317 Carlton Avenue, Suite 200</b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Charlottesville, Virginia</b></p>
			</td>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>&nbsp;</b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>22902</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Address of principal executive offices)</p>
			</td>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Zip Code)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(434) 220-0718</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Registrant&#8217;s telephone number, including area code)</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Not applicable</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Former name or former address, if changed since last report)</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="margin-left:0.1%;width:99.9%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; border-color: rgb(0, 0, 0); border-style: solid; border-width: thin thin 1px; width: 33.3%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: justify;">Title of each class</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 33.3%; border-top: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: justify;">Trading Symbol(s)</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 33.3%; border-top: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: justify;">Name of each exchange on which registered</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 33.3%; border-left: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: justify;">Common Stock, par value $0.001 per share</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 33.3%; border-right: thin solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: justify;">DFFN</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 33.3%; border-right: thin solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: justify;">Nasdaq Capital Market</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Emerging growth company&nbsp;&nbsp; </b>&#9744;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp; </b>&#9744;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Item </b><b>8</b><b>.01 </b><b>Other Events</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">On June 1, 2020, Diffusion Pharmaceuticals Inc. (the &#8220;Company&#8221;) issued a press release announcing that the Company has regained compliance with the Nasdaq Stock Market LLC minimum bid price requirement. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Item&nbsp;9.01 &#8211; Financial Statements and Exhibits</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>(d) Exhibits </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <a href="ex_188766.htm" style="-sec-extract:exhibit;">Press release issued June 1, 2020</a></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>SIGNATURES</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td style="width: 53%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;">Dated: June 1, 2020&nbsp;</p>
			</td>
			<td colspan="2" style="width: 2%;" valign="top" width="38%">
			<p style="margin-top: 0; margin-bottom: 0;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
			</td>
			<td style="width: 10%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 53%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 2%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 35%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 10%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 53%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 2%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" style="width: 35%;" valign="bottom" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 10%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left; width: 53%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left; width: 2%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="width: 35%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; /s/ David G. Kalergis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></p>
			</td>
			<td style="width: 10%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 53%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" rowspan="1" style="width: 2%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;">Name: David G. Kalergis</p>
			</td>
			<td style="width: 10%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 53%;" valign="top" width="50%">&nbsp;</td>
			<td colspan="2" style="width: 2%;" valign="top" width="3%">Title:&nbsp;&nbsp; Chief Executive Officer</td>
			<td style="width: 10%;" valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 53%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 2%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 35%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 10%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_188766.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_188766.htm</title>

	<!-- Generated by ThunderDome Portal - 6/1/2020 4:31:57 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="margin: 0pt; text-align: right;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin: 0pt; text-align: left;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<div style="margin: 0pt;"><img alt="" src="logo.jpg"></div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>Diffusion Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><i>Share price exceeds $1 at closing for 10 consecutive trading days</i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>&nbsp;</i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>CHARLOTTESVILLE, </b><b>Va. </b><b>(June </b>1<b>, 2020) &#8211; Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) </b>(&#8220;Diffusion&#8221; or &#8220;the Company&#8221;) announces that on May 29, 2020 it received written notice from the Nasdaq Listing Qualifications Staff of the NASDAQ Stock Market LLC (&#8220;Nasdaq&#8221;) stating that the Company regained compliance with the applicable Nasdaq minimum bid price continued listing standard and the matter is now closed.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The Company had previously been notified by Nasdaq on December 11, 2019 that it was not in compliance with the minimum bid price rule because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. In order to regain compliance with Listing Rule 5550(a)(2), the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, which was achieved on May 28, 2020. The Company&#8217;s last closing bid price on May 28 was $1.27. This development means that while the Company is still seeking authority from its stockholders for a reverse split of the Company&#8217;s common stock, it is not currently anticipated that the board will implement a reverse split at this time, absent a change in the market price of the Company&#8217;s common stock.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>About Diffusion Pharmaceuticals Inc.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Diffusion Pharmaceuticals Inc. is an innovative biotechnology company developing new treatments that improve the body&#8217;s ability to deliver oxygen to the areas where it is needed most, offering new hope for the treatment of life-threatening medical conditions. Diffusion&#8217;s lead drug trans sodium crocetinate (TSC) was originally developed in conjunction with the U.S. Office of Naval Research, which was seeking a way to treat multiple organ failure and its resulting mortality caused by low oxygen levels from blood loss on the battlefield. Evolutions in research have led to Diffusion&#8217;s focus today on addressing some of medicine&#8217;s most intractable and difficult-to-treat diseases, including multiple organ failure from respiratory distress, stroke and glioblastoma multiforme (GBM) brain cancer. In each of these diseases, lack of available oxygen presents a significant obstacle for medical providers and is the target for TSC&#8217;s novel mechanism.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In 2019, the Company reported favorable safety data in a 19-patient dose-escalation run-in to its Phase 3 INTACT program, using TSC to target inoperable GBM. That trial is currently paused, while the Company prioritizes its resources to address COVID-19. Diffusion&#8217;s in-ambulance PHAST-TSC trial for acute stroke began enrolling patients last year. Given the heightened responsibilities of the Company&#8217;s emergency medical services providers, enrollment in this trial, while not officially paused, is expected to be minimal until the COVID-19 pandemic abates. The Company is currently partnering with both U.S. and European- based institutions in an expedited research program to develop TSC as a treatment for the low oxygen levels and associated multiple organ failure in COVID-19 patients.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Preclinical data supports the potential for TSC as a treatment for other conditions where low oxygen availability plays an important role, such as myocardial infarction, peripheral artery disease, and neurodegenerative conditions such as Alzheimer&#8217;s and Parkinson&#8217;s disease. In addition to the development of TSC, RES-529, the Company&#8217;s PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes, is in preclinical testing for GBM.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Diffusion is headquartered in Charlottesville, Virginia &#8211; a hub of advancement in the life science and biopharmaceutical industries &#8211; and is led by CEO David Kalergis, a 30-year industry veteran and company co-founder.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>Forward-Looking Statements</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the company's plans, objectives, expectations and intentions with respect to future operations and products, the potential of the company's technology and product candidates, and other statements that are not historical in nature, particularly those that utilize terminology such as "would," "will," "plans," "possibility," "potential," "future," "expects," "anticipates," "believes," "intends," "continue," "expects," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause the Diffusion&#8217;s actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular uncertainties and risks include the various risk factors (many of which are beyond Diffusion&#8217;s control) as described under the heading &#8220;Risk Factors&#8221; in Diffusion&#8217;s filings with the United States Securities and Exchange Commission. All forward-looking statements in this news release speak only as of the date of this news release and are based on management's current beliefs and expectations. Diffusion undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Contacts:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">David Kalergis, CEO</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Diffusion Pharmaceuticals Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">(434) 825-1834</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><u>dkalergis@diffusionpharma.com</u></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">or</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">LHA Investor Relations</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Kim Sutton Golodetz</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">(212) 838-3777</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><u>&nbsp;</u><u>kgolodetz@lhai.com</u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"># # #</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  P ) # 2(  A$! Q$!_\0
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M\%*9/V:8_AWXKAUV+Q/<^&/[:>[MOL1D@61C+LW>9M/EG QGD4#9]^T5\/\
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M).<Y^\*^33_P;0?M(_$K1;#PWX\_:I^V>$+5%MO[.B?4[^&&W4 (B0RRI$0
MH 4C  % CYHU_P 16W_!4?\ X.1+#5O!/F:CX>N/&EC/%?6O*R:;I$<7FWF3
MG"/]F)4G@[T_O"NE_P""W?\ RL/^&O\ L)>$/_1L-?KO_P $SO\ @CM\+?\
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M'_!/G7_#W[0GCKXD>*]3\9:)J/Q9^(^DSP_V19B1HM!T\*(T4L5 8J3&&P>
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J"6X)^OO#U_=:EHEI-?6JV-[+!&]Q;+*)1;R%060.  VTY&<<XS5&)__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
